Bulletin du Cancer
MENUTargeted therapies in hepatocellular carcinomas: recent results and future development Volume 96, issue 5, mai 2009
Figures
Service de cancérologie, hôpital Beaujon, 100, boulevard du Général-Leclerc, 92110 Clichy, France
- Key words: hepatocellular carcinoma, targeted therapy, phase II, unresectable, EGFR, VEGF/VEGFR
- DOI : 10.1684/bdc.2009.0863
- Page(s) : 553-61
- Published in: 2009
Hepatocellular carcinoma (HCC) is one of the 5th most common cancers around the world with a limited number of systemic therapeutic options. Cytotoxic agents, hormonotherapy and immunotherapy have failed to demonstrate benefit compared to best supportive care in patients with advanced HCC. The recent development of targeted therapies provided hope for the treatment of advanced HCC. We reviewed phases II-III trials presented in 2007 and 2008. Results are promising with a clinical benefit reported with molecular therapies targeting EGF/EGFR and VEGF/VEGFR pathways.